Abstract
Abstract Studies show that 1 in 4 COVID-19 patients are afflicted with chronic, or long hauler, symptoms. This means that approximately 12 million Americans continue to suffer from COVID weeks and months after the active infection subsides. The long hauler symptoms include hypoxemia (low SaO2), fatigue, coughing/sneezing, trouble breathing, body aches and headaches. N115 (EmphyCorp/Cellular Sciences Inc.) is a clinical grade sodium pyruvate nasal spray currently under evaluation by the FDA for the treatment of COPD, Pulmonary Fibrosis and other chronic respiratory diseases. This study examined the effects of N115 treatment on the symptoms associated with COVID-19 long haulers. We have observed significant improvement in SaO2 levels, trouble breathing and fewer headaches indicating that N115 is a potential therapeutic for a major disease with few current options for treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
